Korea Investment CORP Grows Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Korea Investment CORP raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 77.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 196,912 shares of the biopharmaceutical company’s stock after buying an additional 86,057 shares during the quarter. Korea Investment CORP owned about 0.15% of Alnylam Pharmaceuticals worth $89,792,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. Norges Bank bought a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $662,837,000. Holocene Advisors LP bought a new stake in Alnylam Pharmaceuticals in the second quarter valued at $194,616,000. Orbis Allan Gray Ltd boosted its holdings in Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after acquiring an additional 486,489 shares in the last quarter. Massachusetts Financial Services Co. MA purchased a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at $162,577,000. Finally, Vanguard Group Inc. increased its position in Alnylam Pharmaceuticals by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after purchasing an additional 268,313 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $320.66 on Friday. The company’s fifty day moving average price is $352.25 and its 200-day moving average price is $414.49. The stock has a market cap of $42.53 billion, a PE ratio of 187.52 and a beta of 0.36. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter in the previous year, the business earned ($0.65) earnings per share. The firm’s revenue was up 84.9% compared to the same quarter last year. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam signed a research collaboration with Tenaya Therapeutics to discover and validate genetic targets for cardiovascular disease — deal includes about $10M upfront plus up to $1.13B in milestones, expanding Alnylam’s RNAi opportunity set beyond liver/rare diseases. Tenaya deal
• Positive Sentiment: Alnylam struck a multi‑year precision‑medicine agreement with Helix to accelerate target discovery and patient stratification — a collaboration that could improve R&D efficiency and help de‑risk development programs. Helix agreement
• Positive Sentiment: Coverage notes a Canada reimbursement decision for AMVUTTRA and ongoing trial progress for pipeline assets — these commercial developments improve near‑term revenue visibility for marketed RNAi drugs. AMVUTTRA reimbursement
• Neutral Sentiment: The market reaction to Tenaya’s stock after the deal (TNYA pulled back after a strong rally) shows partner‑stock volatility but does not directly change Alnylam’s deal economics. TNYA market reaction
• Neutral Sentiment: Short‑interest reports showing “0 shares” / 0.0 days to cover are likely a reporting glitch and are not a real driver of positioning today.
• Negative Sentiment: Multiple insiders, including CEO Yvonne Greenstreet and several EVPs, disclosed share sales (early March filings). Clustered insider selling can create near‑term negative sentiment and add selling pressure despite insiders still holding large stakes. CEO SEC filing InsiderTrades summary
• Negative Sentiment: Recent quarterly results (reported Feb. 12) missed EPS and revenue estimates, which keeps valuation under scrutiny and may limit upside until clearer revenue traction is sustained.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 6,799 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $2,227,692.35. Following the completion of the transaction, the chief executive officer owned 98,628 shares of the company’s stock, valued at approximately $32,315,464.20. This trade represents a 6.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total transaction of $528,193.96. Following the transaction, the executive vice president owned 21,860 shares of the company’s stock, valued at $6,989,297.80. The trade was a 7.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 53,923 shares of company stock valued at $18,072,087. Insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

ALNY has been the subject of several research analyst reports. Truist Financial dropped their target price on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research report on Thursday, January 8th. Chardan Capital reduced their price target on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Wells Fargo & Company lowered their price objective on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a report on Tuesday, January 20th. Finally, Stifel Nicolaus lifted their price objective on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $477.96.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.